Stock Analysis

Terumo Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

TSE:4543
Source: Shutterstock

Terumo (TSE:4543) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥263.6b (up 10% from 3Q 2024).
  • Net income: JP¥35.4b (up 19% from 3Q 2024).
  • Profit margin: 13% (in line with 3Q 2024).
  • EPS: JP¥23.97 (up from JP¥20.03 in 3Q 2024).
earnings-and-revenue-growth
TSE:4543 Earnings and Revenue Growth February 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Terumo Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 2.8%.

Looking ahead, revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Japan.

Performance of the Japanese Medical Equipment industry.

The company's shares are down 1.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Terumo's balance sheet and an in-depth analysis of the company's financial position.

Valuation is complex, but we're here to simplify it.

Discover if Terumo might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:4543

Terumo

Engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.

Flawless balance sheet with solid track record.